Mitsubishi Tanabe Pharma Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mitsubishi Tanabe Pharma Corporation
Building on 20 years of work and positive preclinical data, and backed by a fresh injection of cash, Alentis is taking its liver fibrosis candidate into Phase I trials in the fourth quarter.
Public Company Edition: The pace of US initial public offerings slowed a bit in April and May but could ramp back up in June as biopharma investor sentiment rebounds. Also, drug developers continue to go public via SPAC mergers, most recently Valo Health with a $2.8bn post-deal valuation.
Pieris and Genentech try partnering again after a disappointing IO tie-up before. Biogen’s hectic May includes partnerships with Ginkgo, Envisagenics, Capsigen and an opt-in on TMS’s stroke candidate.
Having been given a PDUFA target date of 1 January, 2022, Strongbridge is already preparing for a happy new year challenging Recordati's Isturisa for market share in the Cushing's syndrome space
- Drug Delivery
- OTC, Consumer
Drug Discovery Tools
- Natural Products
- Molecular Diversity
- Drug Discovery Tools
- Other Names / Subsidiaries
- BIXEN Corporation
- Medicago Inc.
- Mitsubishi Tanabe Pharma America, Inc. (MTPA)
- Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA)
- Mitsubishi Tanabe Pharma Singapore Pte. Ltd.
- NeuroDerm, Ltd. (NDRM)
- PT Mitsubishi Tanabe Pharma Indonesia
- Mitsubishi Tanabe Pharma (Thailand)
- MT Pharma Singapore PTE. Ltd.
- Tai Tien Pharmaceuticals Co., Ltd.
- Tanabe Research Laboratories U.S.A.